Getting Cardiovascular: Baseline Risk and Hypertension Treatment and Dual Antiplatelet Therapy in Coronary Stents

Subscribe on iTunes

This Week: Baseline cardiovascular risk calculators and hypertension treatment, and dual antiplatelet treatment after coronary stenting

This week, Fahad and Amol want you to understand that:

1. A cardiovascular risk calculator can predict the degree of treatment benefit that patients may derive  from blood pressure treatment.

2. There is limited evidence to recommend continuing dual antiplatelet therapy beyond 12 months after coronary stenting.

Continuing Medical Education

Internists can receive 0.5 hours of Continuing Medical Education credit for each podcast they listen to through the Canadian Society of Internal Medicine (MOC Category 1) and the American Medical Association (PRA Category 1). To receive CME credit for listening to this podcast, please click here to fill out our Evaluation and Impact Assessment Form.

The papers

The Blood Pressure Lowering Treatment Trialists’ Collaboration. Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data. Lancet. 2014 Aug 16;384(9943):591-8. (PubMed).

P Verdecchia and G Reboldi. Risk and decision making in patients with hypertension. Lancet 2014 Aug 16;384(9943):562-4. (PubMed).

JP Collet et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014 Jul 15. pii: S0140-6736(14)60612-7. (PubMed).

Good stuff


B. Gaudilliere et al. Clinical recovery from surgery correlates with single-cell immune signatures. Sci Transl Med 2014 Sep 24: 255(6): 255ra131.

Pam Belluck. After Surgery, Predicting a Speedy Recovery. New York Times. Sept 29, 2014.


Eduardo Porter. A Dearth in Innovation for Key Drugs. New York Times, July 22, 2014. 


Please help us evaluate The Rounds Table by filling out our survey.

Leave a Comment

Your email address will not be published. Required fields are marked *

Republish this article

Republish this article on your website under the creative commons licence.

Learn more